Our Latest News - BUHLMANN

BUHLMANN News

ENTRETIEN AVEC CARMELA GUGLIOTTA, Laborgemeinschaft 1, Zurich

fCAL® turbo de BÜHLMANN Santé Canada Licence: 96808 English Version ENTRETIEN AVEC CARMELA GUGLIOTTA, Laborgemeinschaft 1, Zurich Vous avez dernièrement choisi d’utiliser le nouveau test fCAL® turbo de BÜHLMANN® turbo sur votre Cobas® c501 de Roche. Pourriez-vous nous indiquer les raisons de votre choix ? Nos clients nous ont demandé s’il était possible que notre laboratoire
Continue Reading

Visit BUHLMANN Diagnostics Corp at AACC 2017

  AACC 2017 BUHLMANN Diagnostics Corp  Booth: #1620 July 30 – August 3 2017, 2017 San Diego Convention Center | San Diego, CA     LEARN MORE Click & Contact AACC 2017 BUHLMANN Team Connect with our team ahead of time, learn more about the BÜHLMANN's Products and Solutions or schedule a meeting! Collin Shaw, VP of Business Development
Continue Reading

Turbidimetric Determination of Fecal Calprotectin Using Two Table Top Chemistry Analyzers: Mindray BS-200E and Cobas® c111

BÜHLMANN fCAL® turbo: Mandic-Havelka, A. Nilsen, T. et. al. Turbidimetric Determination of Fecal Calprotectin Using Two Table Top Chemistry Analyzers: Mindray BS-200E and Cobas® c111.  Clin Lab.  2017 May 1;63(5):907-913. doi: 10.7754/Clin.Lab.2016.161032.  PMID: 28627817 Highlights from this Publication “The assay was linear in the range between 20 and 1,900 µg/g with a limit of quantification around 20
Continue Reading

Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity

IBDoc® Citation: Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF, Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity, Clinical Gastroenterology and Hepatology (2017) Jun 9. pii: S1542-3565(17)30712-7. DOI:10.1016/j.cgh.2017.06.007,  PMID:28606846. Highlights from this Publication “… we showed that the smartphone reader used by patients
Continue Reading

Usability of a Home-Based Test for the Measurement of Fecal Calprotectin in Asymptomatic IBD Patients Digestive and Liver Disease

IBDoc® Citation: Bello C, Roseth A, Guardiola J, Reenaers C, Ruiz-Cerulla A, Kemseke C Van, Arajol C, Reinhard C, Seidel L, Louis E.Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Digestive and Liver Disease. 2017 May 19. pii: S1590-8658(17)30886-1. http://dx.doi.org/10.1016/j.dld.2017.05.009 PMID: 28587751 Highlights from this Publication “ …Globally, the correlation between
Continue Reading

BUHLMANN LabSense News: Spring 2017 Edition

BUHLMANN Diagnostics Corp is proud to release the third edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News.  Here you will also be able to access valuable resources, applications, and other newsworthy items specific to fields of in vitro diagnostics and scientific research. In this edition,
Continue Reading

Correlation of Rapid Point-of-Care vs Send-Out Fecal Calprotectin Monitoring in Pediatric Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL extended Citation: Rodriguez, A. et al.  Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease. World J Gastrointest Pharmacol Ther 8(2):127-130. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.127. Highlight from this Publication “In summary, we present the first correlation study of rapid POC calprotectin testing in a pediatric IBD
Continue Reading

Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide

BÜHLMANN fCAL® ELISA: Heidi A, Park KT, Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis. 2017 Jun;23(6):894-902. doi: 10.1097/MIB.0000000000001082. PMID: 28511198 Highlights from this Publication “This systematic review shows that the relapsing remitting nature of IBD becomes less unpredictable
Continue Reading

Visit BUHLMANN at DDW 2017- Booth 1925

Digestive Diseases Week (DDW) 2017 BUHLMANN Diagnostics Corp  Booth: #1925 May 06 - 09, 2017 | McCormick Place | Chicago, IL Learn More Click & Contact DDW 2017 BUHLMANN Team Connect with our team ahead of time, learn more about our Calprotectin Assays or schedule a meeting! Collin Shaw, VP of Business Development Jennifer Stuart, Technical
Continue Reading

BUHLMANN Highlights: GanglioCombi MAG ELISA

BÜHLMANN GanglioCombi® MAG ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100476 DOWNLOAD WHITE PAPER BÜHLMANN GanglioCombi® MAG ELISA Comprehensive assay for anti-MAG and most prevalent anti-Ganglioside antibodies: (GM1, GM2, GD1a, GD1b, and GQ1b). The Neuroimmunology product line by BÜHLMANN is a list of robust assays for simple, esoteric
Continue Reading